← Leaderboards
Jianqiang Wu
Cincinnati Childrens Hosp Med Ctr
$4,001,356
Attributed
$4,594,445
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $815.2K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,594,445 · 3
By mechanism
R01$3,408,267 · 1
R33$788,678 · 1
R61$397,500 · 1
Top collaborators
- Nancy Ratner3 shared
Most similar at Cincinnati Childrens Hosp Med Ctr
Same institution · by research overlap
- Nancy Ratner$25,011,276
- Jonathan Scott Fletcher$80,820
Others in their field
Top investigators on “Pathway Interactions”
- David Heimbrook · Leidos Biomedical Research, Inc.$202,777,247
- Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
- David R. Weir · University Of Michigan At Ann Arbor$129,316,139
- Daniel Ernest Ford · Johns Hopkins University$108,075,637
- David W Simpson · University Of Southern California$88,046,235
- Charles D. Blanke · Oregon Health And Science University$86,571,896
Research focus
Pathway InteractionsBenignPrincipal InvestigatorTherapeutic EffectApoptosisGrowthTumorProgramsNeurofibromaNeurofibromatosis 1Malignant NeoplasmsIn VivoCell ProliferationMagnetic Resonance ImagingAffectMouse ModelNeoplastic CellClinical TrialsLanguageMaintenanceMolecularNovel Therapeutic InterventionNovel TherapeuticsCells
Grant awards (12)
MiR-155 and RUNX function in neurofibroma tumorigenesis and therapy$429,779
R01 · FY2025 · NS · contact PI
MiR-155 and RUNX function in neurofibroma tumorigenesis and therapy$416,885
R01 · FY2024 · NS · contact PI
MiR-155 and RUNX function in neurofibroma tumorigenesis and therapy$431,338
R01 · FY2023 · NS · contact PI
MiR-155 and RUNX function in neurofibroma tumorigenesis and therapy$424,015
R01 · FY2022 · NS · contact PI
Targeting Complement 5a-Mediated Immunoregulation for Neurofibroma Therapy$391,227
R33 · FY2022 · NS · contact PI
Targeting Complement 5a-Mediated Immunoregulation for Neurofibroma Therapy$397,451
R33 · FY2021 · NS · contact PI
miR-155 and RUNX function in neurofibroma tumorigenesis and therapy$341,250
R01 · FY2020 · NS · contact PI
Targeting complement 5a-mediated immunoregulation for neurofibroma therapy$397,500
R61 · FY2019 · NS · contact PI
miR-155 and RUNX function in neurofibroma tumorigenesis and therapy$341,250
R01 · FY2019 · NS · contact PI
miR-155 and RUNX function in neurofibroma tumorigenesis and therapy$341,250
R01 · FY2018 · NS · contact PI
miR-155 and RUNX function in neurofibroma tumorigenesis and therapy$341,250
R01 · FY2017 · NS · contact PI
miR-155 and RUNX function in neurofibroma tumorigenesis and therapy$341,250
R01 · FY2016 · NS · contact PI